A player in the bustling microbiome R&D arena promotes its CSO to the top post -- just ahead of a PhII NASH study
There’s been a change of leadership — and strategy — at one of the Bay Area biotechs looking to play a prominent role in microbiome R&D. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
